| 1.1 Proportion of patients with improvement according to global judgement of patient: subgrouped by diagnosis |
11 |
606 |
Risk Ratio (M‐H, Random, 95% CI) |
1.30 [1.05, 1.60] |
| 1.1.1 Ménière's (investigator‐defined) |
3 |
139 |
Risk Ratio (M‐H, Random, 95% CI) |
1.56 [0.92, 2.65] |
| 1.1.2 BPPV |
1 |
63 |
Risk Ratio (M‐H, Random, 95% CI) |
1.34 [0.85, 2.10] |
| 1.1.3 Other vertigo |
8 |
404 |
Risk Ratio (M‐H, Random, 95% CI) |
1.24 [0.97, 1.58] |
| 1.2 Proportion of patients with improvement according to global judgement of patient: subgrouped by drug dose |
11 |
606 |
Risk Ratio (M‐H, Random, 95% CI) |
1.45 [1.09, 1.94] |
| 1.2.1 Betahistine dose less than 48 mg per day |
6 |
292 |
Risk Ratio (M‐H, Random, 95% CI) |
2.11 [1.03, 4.30] |
| 1.2.2 Betahistine dose 48 mg or over per day |
5 |
314 |
Risk Ratio (M‐H, Random, 95% CI) |
1.16 [0.92, 1.48] |
| 1.3 Proportion of patients with adverse effects |
12 |
819 |
Risk Ratio (M‐H, Random, 95% CI) |
1.03 [0.76, 1.40] |
| 1.4 Proportion of patients with upper gastrointestinal adverse effects |
6 |
587 |
Risk Ratio (M‐H, Random, 95% CI) |
1.38 [0.67, 2.82] |
| 1.5 Proportion of patients with headache |
4 |
515 |
Risk Ratio (M‐H, Random, 95% CI) |
0.88 [0.15, 5.19] |
| 1.6 Withdrawal from study |
8 |
481 |
Risk Ratio (M‐H, Random, 95% CI) |
0.96 [0.65, 1.42] |
